Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases

Clinical and Experimental Medicine

Volumn 13, Issue 3, 2013, Pages 177-186

  Ramos, José M ^a,b   Masiá, Mar ^a,b   Rodríguez, Juan C ^a   López, Cristina ^a   Padilla, Sergio ^a   Robledano, Catalina ^a   Navarro Blasco, Francisco J ^a   Matarredona, Jaime ^a   García Sepulcre, Mariana F ^a   Gutiérrez, Félix ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Antitumor necrosis factor ; Immunosuppressive therapy; Inflammatory bowel disease; Psoriasis; QuantiFERON TB; Rheumatoid arthritis; Tuberculin skin test

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; LEFLUNOMIDE; METHOTREXATE; TUBERCULINA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DIAGNOSTIC TEST; ENTERITIS; FEMALE; HIDRADENITIS; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; QUANTIFERON TB TEST; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULIN TEST;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84881475792     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0192-7     Document Type: Article

References (39)

1. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF (2008) Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57:549-558
2. Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291-302
3. Gómez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthr Rheum 57:756-761
4. Ledingham J, Wilkinson C, Deighton C (2005) British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology (Oxford) 44:1205-1206
5. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, BIOBADASER Group, et al. (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum 52:1766-1772
6. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360-1361
7. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2:309-313
8. Lalvani A, Pareek M (2010) Interferon gamma release assays: principles and practice. Enferm Infecc Microbiol Clin 28:245-252
9. Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177-184
10. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. (2011) Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37:88-99
11. Cellestis Limited QuantiFERON-TB Gold. Available at: http://www. cellestis.com. Accessed 20 February 2011
12. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC) (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 59(RR-5):1-25
13. Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puéchal X, RATIO (Research Axed on Tolerance of Biotherapies) Study Group, et al. (2007) Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66:1610-1615
14. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al. (2008) Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 27:907-913
15. Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, Seibold F (2008) Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 103:2799-2806
16. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35:776-781
17. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthr Rheum 59:800-806
18. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, et al. (2010) Comparison of interferon gamma release assays and conventional screening tests before tumour necrosis factor alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 69:181-185
19. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H (2009) Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 36:2675-2681
20. Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M, Itoh R, Sato S, Ueda R (2010) Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol 20:18-23
21. Chiu HY, Hsueh PR, Tsai TF (2011) Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 164:553-559
22. Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. doi: 10.1002/ibd.21605
23. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. (2011) QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 7:77-83
24. Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, et al. (2011) Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol. doi: 10.1007/s10067-011-1771-1779
25. Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M, et al. (2011) Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients. J Infect Chemother. doi: 10.1007/s10156-011-0250- 1
26. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Chair of Guideline Group, et al. (2009) British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 161:987-1019
27. Diel R, Hauer B, Loddenkemper R, Manger B, Krüger K (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63:329-334
28. Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. (2007) Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 137:620-622
29. American Thoracic Society: Centers for Disease Control and Prevention (2000) Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Car Med 161:1376-1395
30. Landis JR, Koch GC (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
31. Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, et al. (2009) Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36:1876-1884
32. Gogus F, Günendi Z, Karakus R, Erdogan Z, Hizel K, Atalay F (2010) Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population. Clin Exp Med 10:173-177
33. Matulis G, Jüni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67:84-90
34. Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, et al. (2010) Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 69:782-784
35. Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW, et al. (2007) Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 9:207
36. Creed TJ, Lee RW, Newcomb PV, di Mambro AJ, Raju M, Dayan CM (2009) The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol 183:164-171
37. De A, Blotta HM, Mamoni RL, Louzada P, Bertolo MB, Foss NT, et al. (2002) Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis. J Rheumatol 29:46-51
38. Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA, et al. (2005) Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 19:2038-2041
39. Clark SA, Martin SL, Pozniak A, Steel A, Ward B, Dunning J, et al. (2007) Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 150:238-244